Allergan Aesthetics gains Health Canada approval for Boey neurotoxin

• Allergan Aesthetics (NYSE:ABBV) received Health Canada approval for Boey (trenibotulinumtoxinE) to treat moderate to severe glabellar lines in adults.
• Boey is the first serotype E aesthetic neurotoxin with onset of action in about eight hours and duration of two to three weeks.
• The approval introduces a new short-duration option for patients seeking rapid but temporary improvement in frown lines.

Allergan Aesthetics (NYSE:ABBV) received Health Canada approval for Boey (trenibotulinumtoxinE) to temporarily improve the appearance of moderate to severe glabellar (frown) lines in adults.

Boey is the first approved serotype E aesthetic neurotoxin in Canada.

The product offers rapid onset of results in about eight hours and a short duration of roughly two to three weeks.

Allergan Aesthetics stated the new neurotoxin provides an additional treatment choice for patients and practitioners seeking faster onset with shorter effect duration.

Boey expands Allergan Aesthetics’ portfolio of neuromodulators used in medical aesthetics procedures.

Allergan Aesthetics continues to focus on developing differentiated aesthetic products to meet varied patient needs in the growing facial aesthetics market.